NewAmsterdam Pharma (NAMS) Interest & Investment Income (2021 - 2026)

NewAmsterdam Pharma has disclosed Interest & Investment Income across 6 years of filings, most recently posting $5.6 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $5.6 million, down 23.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.9 million (up 22.42% YoY), and the FY2025 annual result was $27.6 million, up 63.45% from the prior year.
• Interest & Investment Income came in at $5.6 million for Q1 2026 at NewAmsterdam Pharma, down from $6.5 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $7.4 million in Q1 2025 to a low of $11.22 in Q4 2022.
• The 5-year median for Interest & Investment Income is $4.5 million (2023), against an average of $4.4 million.
• Across the five-year window, Interest & Investment Income soared 23773100.77% in 2023 and declined 23.14% in 2026, its largest moves.
• NewAmsterdam Pharma's Interest & Investment Income stood at $11.22 in 2022, then soared by 23773100.77% to $2.7 million in 2023, then jumped by 68.1% to $4.5 million in 2024, then soared by 44.33% to $6.5 million in 2025, then declined by 12.71% to $5.6 million in 2026.
• The last three Interest & Investment Income figures came in at $5.6 million (Q1 2026), $6.5 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.